

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Thirty-fourth Report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF 168.00/US\$ 151.00 (CHF 128.40/US\$ 115.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

942

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Thirty-fourth Report



**World Health
Organization**

Geneva 2006

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Drug Dependence. Meeting (34th: 2006: Geneva, Switzerland)
WHO Expert Committee on Drug Dependence: thirty-fourth report.

(WHO technical report series; no. 942)

1. Psychotropic drugs - classification. 2. Psychotropic drugs - pharmacology. 3. Drug
and narcotic control. 4. Treaties. 5. Guidelines. I. World Health Organization.
II. Title. III. Series.

ISBN 92 4 120942 9

(NLM classification: WM 270)

ISBN 978 92 4 120942 7

ISSN 0512-3054

© World Health Organization 2006

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for non-commercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Switzerland
Printed in Switzerland**

Contents

1. Introduction	1
2. Critical review of psychoactive substances	1
2.1 Substances recommended for changes in scheduling	2
2.1.1 Dronabinol (INN)	2
2.1.2 Oripavine	4
2.2 Other substances critically reviewed	5
2.2.1 Buprenorphine (INN)	5
2.2.2 Butorphanol (INN)	8
2.2.3 Ketamine (INN)	9
2.2.4 Khat (<i>Catha edulis</i> Forsk.)	10
2.2.5 Zopiclone (INN)	12
3. Pre-review of psychoactive substances	13
3.1 Gamma-hydroxybutyric acid	13
3.2 Tramadol (INN)	14
4. Substances identified for future pre-review	15
4.1 Gamma-butyrolactone (GBL)	15
4.2 1,4-Butanediol	16
5. Guidelines for the WHO review of dependence-producing psychoactive substances for international control	16
5.1 Amending the current version of the guidelines	16
5.2 Interpretation of specific aspects of the guidelines	17
5.3 Access to information necessary for the evaluation of substances	18
6. Other matters	18
6.1 Activities of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)	18
6.2 Use of pharmacovigilance data for the assessment of dependence and abuse potential (procedures and methodology)	19
6.3 Promotion of education and information on the appropriate use of psychoactive drugs	19
6.4 Impact of international control on medical availability of substances	20
Acknowledgements	23
References	23

WHO Expert Committee on Drug Dependence

Geneva, 28–31 March 2006

Members*

Dr L. De Lima, IAHPHC Executive Director, International Association for Hospice and Palliative Care, Houston, TX, USA (*Rapporteur*)

Professor R. Fernandopulle, Senior Lecturer, Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

Professor C.R. Schuster, Director, Substance Abuse Research Division & Addiction Research Institute, Wayne State University, Department of Psychiatry and Behavioral Neurosciences, Detroit, MI, USA

Professor S. Suryawati, Director, Centre for Clinical Pharmacology and Medicine Policy Studies, Gadjah Mada University, Yogyakarta, Indonesia (*Vice-chairperson*)

Professor T. Suzuki, Department of Toxicology, School of Pharmacy, Hoshi University, Tokyo, Japan

Dr V. Verachai, Deputy Director, Thanyarak Institute on Drug Abuse, Department of Medical Services, Pathumtani, Thailand

Professor W. Wieniawski, Polish Pharmaceutical Society, Warsaw, Poland (*Chairperson*)

Representatives of other organizations

College on Problems on Drug Dependence (WHO Collaborating Centre for Research and Training in Drug Dependence)

Dr L.S. Harris, Harvey Haag, Professor, Medical College of Virginia, Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Dr R. Sedefov, Project Manager New Drugs and Scientific Committee, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal (*Special guest at first part of meeting*)

International Narcotics Control Board (INCB)

Dr P.O. Emafo, First Vice-President of the Board, INCB, Vienna, Austria

P. Pachta, Deputy Secretary of the Board and Chief, Narcotics Control and Estimates Section, INCB Secretariat, United Nations Office on Drugs and Crime, Vienna, Austria

Joint United Nations Programme on HIV/AIDS (UNAIDS)

Dr A. Chatterjee, Senior Adviser, Prevention, Policy Evidence and Partnerships Department, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland

* Unable to attend: Professor M.S. Bourin, Department of Pharmacology, Faculty of Medicine, University of Nantes, Nantes, France; Dr E.M.A. Ombaka, Director, Ecumenical Pharmaceutical Network, Westlands, Nairobi, Kenya.

United Nations Office on Drugs and Crime (UNODC)

Dr B. Remberg, Scientific Affairs Officer, Laboratory and Scientific Section, UNODC, Vienna, Austria

C. Volz, Chief, Treaty and Legal Affairs Branch, UNODC, Vienna, Austria

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Dr Y. Juillet, Chairperson of the Regulatory Policy and Technical Standards Committee, IFPMA, Geneva, Switzerland

Secretariat

Dr B. Brands, Acting Head, Addiction Medicine Clinic, Assistant Professor, Centre for Addiction and Mental Health, Assistant Professor, Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada (*Temporary adviser*)

Dr S. Elliott, Senior Clinical Scientist, Head of Forensic Toxicology Section, Regional Laboratory for Toxicology, City Hospital, Birmingham, England (*Temporary adviser*)

Dr E.J.M. Pennings, Biochemist–Toxicologist, Oegstgeest, The Netherlands (*Temporary adviser*)

Dr V. Poznyak, Coordinator, Management of Substance Abuse, WHO, Geneva, Switzerland

Dr L. Răgo, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland

Dr W.K. Scholten, Technical Officer, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland (*Secretary*)

Dr T. Schwalbach, Head Anaesthesiologist, Anaesthetic Department, Maputo Central Hospital, Maputo, Mozambique (*Temporary adviser*)

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?>